Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor

Morton Scheinberg a,*, Luis Antônio Machado b, Luiz Guilherme M Castro c, Sineida Berbert Ferreira d, Nilceo Michalany e

a Hospital Israelita Albert Einstein and Centro de Doenças Autoimunes, Hospital Beneficência Portuguesa, São Paulo, Brazil
b Dermatologista Do Centro de Doenças Autoimunes, Hospital Beneficência Portuguesa, São Paulo, Brazil
c Hospital Alemao Oswaldo Cruz - Sao Paulo, Brazil
d Clínica Dermatológica Síneida Berbert Ferreira, Maringá, Brasil
e Laboratório Paulista de Dermatopatologia, Sao Paulo, Brazil

ARTICLE INFO
Keywords:
Pyoderma gangrenosum
Treatment
Baricitinib

ABSTRACT
Pyoderma gangrenosum manifests as an ulceration of the skin often associated with several systemic diseases. The diagnosis is usually made by exclusion criteria with suggestions made by clinical findings and histological features. It can occur any site but more common in the legs. Advances in translational medicine led to the development of new forms of therapy in chronic inflammatory diseases by the oral administration of Janus kinase inhibitors. We report two cases of chronic ulceration of the skin consistent with the diagnosis of Pyoderma Gangrenosum that went into complete remission after the use of baricitinib.

1. Introduction
Pyoderma gangrenosum (PG) is an uncommon cutaneous condition with a challenging diagnosis, given its multifactorial pathogenesis [1,2]. In this research communication, we report on the first successful treatment of two PG patients with the novel JAK inhibitor, baricitinib.

1.1. Case report
A 71-year-old woman with remitting multi-resistant tender papules with a metamic disposition was initially treated as herpes zoster. She later developed a chronic ulcer on the scalp that, after investigation, was indicative of pyoderma gangrenosum (PG) or pyoderma-like. She had a previous history of pulmonary tuberculosis and PG on both legs in 2003. She was treated with cyclosporine, infliximab, clofazimine, doxycycline, and intralesional triamcinolone injections with varying results for over four years. PG was finally controlled in mid-2007. She remained asymptomatic until March 2020, when intense and sudden pain on the vertex and left parietal region developed. Multiple tender papules with peripheral erythema were present. Although no vesicles were found, a tentative diagnosis of cephalic herpes zoster was suspected. Despite treatment with valacyclovir and pregabalin, symptoms increased, and papules evolved into multiple, deep, ulcerated lesions with a central necrotic scab and undermining border. Expression yielded a significant amount of purulent secretion. Skin biopsy findings were of an ulcer with exuberant granulation tissue. Histology study was performed on the material obtained while curetting one of the large abscesses rather than by a wedge excision of the border. Although the vertex aspect on the scalp suggested an erosive pustular dermatosis of the scalp, histology was more consistent with PG. Attempts to obtain microbiological cultures were twice negative.

Previous comorbidities include IgA multiple myeloma in remission for the past seven years and remission of pulmonary tuberculosis treated with triple therapy 18 years ago. In the process of choosing a proper therapy, the Quantiferon test was performed, which was negative. After a short period of use of oral Dapsone, the disease progressed. Due to the previous history of tuberculosis and possible contra-indications for anti-TNF alpha therapy, she was started on baricitinib, a novel Janus kinase (JAK) inhibitor, 4 mg orally daily, taking into consideration the past attempts with more conservative approaches mentioned above. The idea of using JAK inhibitors was considered in the case of failed treatments, which proved helpful. Lesions started to improve, and by seven days, no new lesions were identified. Complete regression was achieved after five weeks, leaving a depressed scar (Fig. 1, Fig. 2).

* Corresponding author.
E-mail address: morton@osite.com.br (M. Scheinberg).

https://doi.org/10.1016/j.jtauto.2021.100099
Received 22 March 2021; Accepted 10 April 2021
2589-9090/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Case 2  A 59-year-old female with rheumatoid arthritis since 2011, controlled with methotrexate 15 mg/week, developed in 2018 a leg skin ulcer for which PG was diagnosed. Healing was obtained with dressings and MTX maintenance.

In 2019, another PG occurred on the left leg and ankle; treatment consisted of prednisone 0.7 mg/kg/d associated with MTX 20 mg/week. PG resolved in 4 months; corticotherapy was gradually tapered, and MTX was maintained. Severe Cushing’s syndrome signs were noted, impairing quality of life.

In 2020, another outbreak of PG compromised the right leg; methotrexate was suspended, and baricitinib 4 mg/day was introduced, with the lesion’s healing in 3 months presented in the photos (Fig. 3, Fig. 4).

2. Discussion

PG is uncommon, challenging to treat with no gold standard therapy. The literature is mainly restricted to case reports, case series, and rare randomized clinical trials.
PG is currently a “diagnosis of exclusion,” where attempts to improve diagnostic accuracy has been addressed in international experts’ consensus and validated diagnostic criteria for ulcerative PG \[3,4\]. In our cases, in which the patient lacked a major diagnostic criterion (biopsy of ulcer edge demonstrating neutrophilic infiltrate), PG diagnosis was based on the presence of several minor criteria mentioned in the consensus, namely: (a) history of papule, pustule, or vesicle ulcerating within four days of appearance; (b) peripheral erythema, undermining border, and tenderness at ulceration site; (c) multiple ulcerations, at least one on an anterior lower leg; (d) cribriform or “wrinkled paper” scar(s) at healed ulcer sites; and (e) decreased ulcer size within one month of initiating immunosuppressive medication(s). In this study, 4 of 8 minor criteria maximized discrimination, yielding sensitivity and specificity of 86% and 90%, respectively.

There is growing evidence on the efficacy of small-molecule Janus kinase inhibitors on the treatment of immune skin disorders by its effect of transduction of intracellular signals from cell surface receptors from various immune-inflammatory cytokines, Baricitinib acts as an oral anticytokine therapy by inhibiting Janus kinase activity \[5–7\]. In a recent paper Baricitinib was shown to affect other immunoinflammatory diseases resistant to steroids. The lack of response observed in our patient and the growing concept that PG is an autoimmune condition where several uncontrolled/untreated comorbidities may serve as a trigger opens the possibility that Baricitinib should be expanded to PG refractory cases where steroids or anti-cytokine therapy fails or is contraindicated \[8\]. Finally, one of our patients had hematological malignancy and the other rheumatoid arthritis. Both conditions have been reported to have an increased association with the development of PG in recent reports \[9,10\]. Patients with rheumatoid arthritis have an increase in the odds to develop PG by threefold, and patients with malignant monoclonal antibody disease are listed as one of the hematological malignancies associated with PG, raised the possibility that skin lesions PG or PG like, rheumatoid arthritis or hematological malignancies should be suspected as an associated disease.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] A. Teagle, R. Harpest, Management of pyoderma gangrenosum, J. R. Soc. Med. 107 (6) (2014) 228–236.
[2] A.V. Marzano, G. Damiani, I. Ceccherini, E. Berti, M. Gattorno, M. Cugno, Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum) acne and suppurative hidradenitis, Br. J. Dermatol. 176 (2017) 228–236.
[3] E. Mavrikas, C. Ma, K. Shinkai, D. Fiorentino, J.P. Callen, U. Wollina, A.V. Marzano, D. Wallach, K. Kim, C. Schadt, A. Ormerod, M.A. Fung, A. Steel, F. Patel, R. Qin, F. Craig, H.C. Williams, F. Powell, A. Merleev, M.Y. Cheng, Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international experts, JAMA Dermatol 154 (4) (2018 Apr 1) 461–466, https://doi.org/10.1001/jamadermatol.2017.5980. PMID: 29450466.
[4] A. Alavi, L.E. French, M.D. Davis, A. Brassard, R.S. Kirsner, Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment, Am. J. Clin. Dermatol. 18 (3) (2017 Jun) 355–372, https://doi.org/10.1007/s40257-017-0251-7. PMID: 28224502.
[5] F. McKenzie, D. Cash, A. Gupta, L.W. Cummings, A.G. Ortega-Loayza, Biologic and small-molecule medications in the management of pyoderma gangrenosum, J. Dermatol. Treat. 30 (3) (2019 May) 264–276, https://doi.org/10.1080/09546634.2018.1506083.
[6] A. Ginz, E. Heck, L. Robertson, Janus kinase inhibitors: a review of their emerging applications in dermatology, Skin Therapy Lett 23 (3) (2018 May) 5–9. PMID: 29772037.
[7] M. Scheinberg, F.C. Malaf, J. Wagner, Steroid-resistant sarcoidosis treated with baricitinib, Ann. Rheum. Dis. (2020) (epub ahead of print).
[8] C. Ahn, D. Negus, W. Huang, Pyoderma gangrenosum: a review of pathogenesis and treatment, Expet Rev. Clin. Immunol. 14 (3) (2018 Mar) 225–233.
[9] C.M. Montagnon, E.A. Fraicca, A.A. Patel, M.J. Camilleri, H. Murad, D. Dingli, D.A. Wetter, S.N. Tokachjov, Pyoderma Gangrenosum in hematological malignancies, J. Am. Acad. Dermatol. 82 (6) (2020 Jun) 1346–1359.
[10] K. Kridrin, G. Damiani, A.D. Cohen, Rheumatoid arthritis and pyoderma gangrenosum: a population-based case control study, Clin. Rheumatol. 40 (2021) 521–529.